News | July 13, 2022
Piramal Pharma Solutions holds opening ceremony for new API Plant at Aurora, Canada
Plant is part of the company's CAD $30 million capital investment in the site
Plant is part of the company's CAD $30 million capital investment in the site
The appointments will add to the well-diversified experience that currently exists on the PPL board.
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Brings 25 years of global operations and supply chain experience to Piramal
Indira IVF has established technological supremacy as the key differentiator, delivering industry leading success rate
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Based on a post hoc analysis, fewer required respiratory interventions
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Subscribe To Our Newsletter & Stay Updated
